Endometrial and breast cancer cells harbouring a range of PI3K/AKT/mTOR pathway mutations were treated in vitro with concentrations of drug that reflect free-drug exposures in patients treated with these agents (i.e. clinically relevant concentrations of each agent, representing Caverage, Cmaximum and mid-point of these). This evidence concerns the gene PIK3CA and breast cancer.